作者
Carlo Andrea Pivato, Davis Jones, Davide Cao, Samantha Sartori, Mauro Chiarito, Johny Nicolas, Zhongjie Zhang, Frans Beerkens, Matteo Nardin, Hanbo Qiu, Victor Razuk, Daniel Feldman, Vaishali Kumaraguru, Giulio G Stefanini, Joseph Sweeny, Usman Baber, George Dangas, Samin K Sharma, Annapoorna Kini, Roxana Mehran
发表日期
2022/6/1
期刊
Canadian Journal of Cardiology
卷号
38
期号
6
页码范围
792-800
出版商
Elsevier
简介
Background
There is a paucity of data on the prognostic value of high-sensitivity C-reactive protein (hsCRP) levels in diabetic and nondiabetic patients undergoing percutaneous coronary intervention (PCI).
Methods
All patients with known baseline hsCRP undergoing PCI at a single tertiary care centre from 2010 to 2017 were included. High hsCRP was defined as > 3 mg/L. Known causes of elevated hsCRP levels and hsCRP > 10 mg/L represented exclusion criteria. The 1-year primary outcome was major adverse cardiovascular events (MACE), including all-cause mortality, myocardial infarction (MI), and target-vessel revascularisation (TVR).
Results
Among a total of 11,979 patients included, high hsCRP levels were observed in 24.7% of patients without diabetes and 29.8% of patients with diabetes (P < 0.001). Both diabetics and nondiabetics with high hsCRP levels had increased rates of MACE compared with …
学术搜索中的文章
CA Pivato, D Jones, D Cao, S Sartori, M Chiarito… - Canadian Journal of Cardiology, 2022